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Abstract
Background: In human breast cancers, amplification of chromosome 11q13 correlates with lymph node
metastasis and increased mortality. To date, two genes located within this amplicon, CCND1 and EMS1, were
considered to act as oncogenes, because overexpression of both proteins, respectively cyclin D1 and cortactin,
correlated well with 11q13 amplification. Cyclin D1 is involved in cell cycle regulation and the F-actin-binding
protein cortactin in cytoskeletal dynamics and cell migration. To study the role of cortactin in mammary gland
tumorigenesis, we examined mouse mammary tumor virus (MMTV)-cortactin transgenic mice and MMTV-
cortactin/-MMTV-cyclin D1 bitransgenic mice.
Methods: MMTV-cortactin transgenic mice were generated and intercrossed with previously described MMTV-
cyclin D1 transgenic mice. Immunohistochemical, Northern and Western blot analyses were performed to study
the expression of human transgene cortactin during mammary gland development and in mammary tumors. For
tumor incidence studies, forced-bred, multiparous mice were used to enhance transgene expression in the
mammary gland. Microscopical examination was performed using haematoxylin and eosin staining.
Results: Mammary gland tumors arose stochastically (incidence 21%) with a mean age of onset at 100 weeks.
This incidence, however, did not exceed that of aged-matched control FVB/N mice (38%), which unexpectedly,
also developed spontaneous mammary gland tumors. We mimicked 11q13 amplification by generating MMTV-
cortactin/-MMTV-cyclin D1 bitransgenic mice but did not observe any synergistic effect of cortactin on cyclin D1-
induced mammary hyperplasias or carcinomas, nor development of distant metastasis.
Conclusion: From this study, we conclude that development of (pre-malignant) breast tumors in either wild type
or MMTV-cyclin D1 mice was not augmented due to mammary gland targeted overexpression of human cortactin.
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Analysis of cortactin transgene expressionFigure 1
Analysis of cortactin transgene expression. (A) Structure of the MMTV-cortactin transgene construct. Vertical striped 
bar, 510 bp promoter/enhancer of the MMTV-LTR (-360/+150); stippled bar, 920 bp β-globin intron 2 sequence inserted to 
generate a stable transgene mRNA; black bar, 1.8 kb human EMS1 cDNA [29]; hatched bar, transcriptional processing 
sequences derived from SV40. Relevant restriction sites are indicated. (B) Southern blot analysis of tail DNA of three cortactin 
transgenic founders and one wild type (WT) mouse. The intensity of the bands corresponds to the increased copy number of 
the integrated transgenic cortactin cDNA. T6 contains one cDNA copy. (C) Northern blot analysis of 10-days lactating mam-
mary glands. Expression of human transgenic cortactin mRNA (3,6 kb) was detected in T16 only. Full-length human cortactin 
cDNA was used as a probe. (D) Western blot analysis of 10-days lactating mammary glands to detect transgenic cortactin pro-
tein expression. Polyclonal antibody RA444 was used to recognize specific human transgene expression, whereas polyclonal 
antibody RA23 recognized both human and endogenous mouse cortactin. (E) Virgin T16 transgenic (T) and non-transgenic 
(W) female mice were treated with glucocorticosteroid dexamethasone to stimulate transgene expression from the MMTV 
promoter. Lysates from liver (Li), salivary gland (SG), kidney (Ki), spleen (Sp), pancreas (Pa), lung (Lu) and 10-days lactating 
mammary gland as a positive control (MG) were subjected to Western blotting. Polyclonal antibody RA444 was used to detect 
specific human transgene expression, whereas monoclonal 4F11 antibody recognizes both human and mouse cortactin. Trans-
gene expression was significantly induced in the pancreas, liver and kidney.
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Background
Breast cancer is the most common form of cancer among
women in Western countries, with approximately one out
of nine being affected in their lifetime [1]. The major
cause of breast cancer mortality is the development of dis-
tant metastasis. Amplification of chromosome 11q13 is
frequently detected in human carcinomas of the breast
[2,3] and correlates with the presence of lymph node
metastases and increased mortality [2,4,5]. Two genes
located within this amplicon, EMS1, encoding cortactin,
and CCND1 encoding cyclin D1, were both considered to
act as oncogenes in breast cancer, because increased
expression of both cortactin and cyclin D1 correlated well
with 11q13 amplification [5-7].
Several lines of evidence point to an important role for
both cyclin D1 as well as EMS1/cortactin in breast cancer
formation. Cyclin D1, involved in cell cycle regulation, is
a well-established human oncogene [8-10]. While the
CCND1 gene is amplified in up to 20% of human breast
cancers, cyclin D1 protein is overexpressed in over 50% of
human mammary carcinomas [3,11-13]. Overexpression
of cyclin D1 seems to have a causative role in breast cancer
formation, since mice containing a mammary-gland tar-
geted MMTV-cyclin D1 transgene develop mammary
tumors at higher incidence (5 out of 9 transgenic mice
compared to none of 15 non-transgenic controls) [14].
However, tumors appeared after a relatively long latency
period of 17.5 months, suggesting that cyclin D1 is a rela-
tively weak oncogene compared to c-neu, Ha-ras and c-
myc oncogenes in MMTV-neu [15], MMTV-ras [16] or
MMTV-myc transgenic mice [17] with a latency period of
respectively 3, 6 and 11 months. Cyclin D1 appears to be
critical in some pathways of mammary tumorigenesis,
because cyclin D1-deficient mice are resistant to breast
cancers induced by the c-neu and Ha-ras oncogene, but
remain fully sensitive to breast cancers induced by c-myc
and Wnt-1 [18].
Cortactin, identified as a prominent Src substrate, is an F-
actin binding protein involved in Arp2/3-mediated actin
polymerization and consequently able to modulate the F-
actin cytoskeleton [19,20] and cell shape changes
(reviewed by [21]). Cells overexpressing cortactin show
enhanced migration [22-24], invasion [22] and increased
metastatic potential in vivo [25]. Thus, increased expres-
sion of cortactin might promote tumor cell invasion and
metastasis. Cancer development and progression is a
multi-step process [26-28], therefore, since both cyclin D1
and cortactin are overexpressed in most breast carcinomas
with 11q13 amplification, their cooperative action might
contribute to breast cancer development.
In the present study, we generated MMTV-cortactin trans-
genic mice to study the effect of mammary gland targeted
cortactin overexpression on morphogenesis of normal
mammary gland development and the potential to induce
mammary gland tumors. To mimic the 11q13 amplifica-
tion and to investigate the possible cooperative action of
cyclin D1 and cortactin, we generated bitransgenic cyclin
D1/-cortactin mice by crossing MMTV-cyclin D1 [14] with
MMTV-cortactin mice.
Methods
Mice and tissue preparation
To generate transgenic mice with targeted expression of
cortactin in the mammary gland, the 1.8 kb EcoRI/BamHI
fragment carrying the open reading frame of the human
EMS1/cortactin cDNA (same fragment as in clone
pGEM42.8/4203 [29]) was cloned into the EcoRI/BglII
sites of the pJ5Ω/HG-vector (pJ5Ω/HG/EMS1/4230; see
Figure 1A) [30]. The pJ5Ω/HG-vector was constructed by
inserting a genomic 920 bp BamHI/EcoRI fragment
including intron 2 with splice donor and acceptor sites of
the human β-globin gene (provided by F. Grosveld, MRC,
London) into the BamHI/EcoRI sites in pJ5Ω supple-
mented with a 5'-MMTV-promotor and 3'-SV40-polyade-
nylation site [31]. The MMTV-LTR in pJ5Ω is an authentic
viral LTR obtained from the C3H mouse mammary tumor
virus (MMTV) and contains the elements required for glu-
cocorticoid regulation, promoter action and capping (-
360/+150). MMTV-cortactin transgenic mice were gener-
ated in the animal colony of the Netherlands Cancer Insti-
tute (Amsterdam) under specific pathogen-free
conditions by microinjection of the transgene into pro-
nuclei of fertilized zygotes as described previously [32].
MMTV-cyclin D1 transgenic mice (MP1 line) were
obtained from Dr. Andrew Arnold (Department of Medi-
cine, Massachusetts General Hospital, Boston, USA.) and
described previously [14]. The MMTV-cyclin D1 mice
used in our experiments have retained inducible expres-
sion of cyclin D1 as detected with Northern blot analysis
on mammary glands of day 10 of lactation (data not
shown). Both cortactin and cyclin D1 transgenic mice
were generated in the same inbred FVB/N genetic back-
ground. All mice were cross-bred and maintained under
restricted conditions in the central animal house at the
department of Pathology (Leiden University Medical
Center). Animal care and experimentation were in accord-
ance with legislation on animal experiments as deter-
mined by the Dutch Veterinary Inspection.
Exclusively female animals were used in the experiments,
and housed with male breeders only for fertilization.
Pregnancy samples were obtained on day 11 or day 17
after vaginal plugs were identified. Lactating mammary
glands were obtained from mice 4, 10 or 17 days after lit-
ters were born. Involution was studied by removing pups
from their mother on day 17 of lactation and obtaining
samples on day 4 or 8 after weaning. For mammary gland
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tumor incidence experiments, mice were kept under
forced-breeding conditions to continuously stimulate
MMTV-driven-mammary-gland targeted transgene expres-
sion. Multiparous females underwent at least 2 but in gen-
eral 3 to 7 successful pregnancies each followed by three
weeks weaning. Mice showing abnormal clinical signs or
discernable tumor development were sacrificed and tis-
sues were macroscopically analyzed and prepared for fur-
ther analysis. For detection of hyperplasias one
abdominal mammary gland was harvested for whole-
mount, the other abdominal mammary gland was frozen
in isopentane (without elimination of the inguinal lymph
nodes) and stored at -80°C; the second and thoracic
mammary glands were fixed in 4% formaldehyde in PBS
and used for histological analysis. The pathology of mam-
mary tumors and premalignant lesions was assessed by
two persons (AGSHR and JHJMK), according to the con-
sensus report from the Annapolis meeting on the mam-
mary pathology of genetically engineered mice [33].
Representative parts of other tissues and organs were fro-
zen and stored at -80°C or fixed in PBS-buffered formal-
dehyde and prepared for histological analysis. To validate
the hormonal inducibility of the MMTV-driven transgene
in vivo, mice were injected intra-peritoneally with 0,25 ml
(4 mg/ml) dexamethasone per mouse during three succes-
sive days and sacrificed on day 4.
DNA analysis and Southern blotting
Genomic DNA was isolated from the tail tip as reported
previously [32] and transgenic progeny was identified by
probing equal amounts of HindIII-digested DNA, electro-
phoresed in a 1% agarose gel and transferred to nitrocel-
lulose membrane (Amersham Biosciences
Buckinghamshire, England). The presence of the trans-
gene was detected by Southern blot analysis with the 1.8
kb EMS1 cDNA probe (pGEM42.8/4203 [30]) and the
0.9-kb cyclin D1 cDNA probe (p3128-CCND1, encom-
passing the coding domain [34]) radiolabeled with [α-
32P] αdCTP (Amersham). The filters were washed two
times at 60°C in 2× SSC; 0.1% SDS for 30 min and the
presence of DNA transgene was determined by phospho-
imaging analysis.
RNA extraction and Northern blotting
Total RNA was isolated from transgenic and non-trans-
genic frozen tissues using the TRIZOL reagent (GIBCO
Invitrogen, Carlsbad, CA, USA) according to the manufac-
turer's protocol. Northern blotting was performed as pre-
viously described [34]. In brief, 10 µg RNA was size
fractionated on a 1% agarose 1% formaldehyde gel, trans-
ferred with 20× SSC (3 M NaCl and 0.3 M sodium citrate)
onto a nitrocellulose membrane (Amersham), washed in
3× SSC, dried, and baked at 80°C for 4 hours. Blots were
hybridized with the [32P]-αdCTP-labeled 1.8-kb EMS1
cDNA probe (pGEM42.8/4203 [30]) at 55°C in sodium
phosphate hybridization mix (0,5 M Na2HPO4, 0,5 M
NaH2PO4, 7% SDS, 1 mM EDTA, 1% BSA, pH = 7). The
filters were washed two times at 60°C in 0,1× SSC;1% SDS
for 15 min and RNA transgene expression was determined
by phospho-imaging analysis.
Protein extraction and Western blotting
Approximately 10 frozen sections (20 µm) of frozen trans-
genic and non-transgenic tissue were dissolved in Hot-
SDS (1%SDS/10 mM EDTA and 1 tablet of complete pro-
tease inhibitors (Roche, Mannheim, Germany) per 50 ml
lysisbuffer). The protein concentration was determined
using the Biorad Protein assay kit. Lysates (100 µg pro-
tein) added with Laemmli sample buffer were boiled and
separated by 10% SDS-PAGE. Proteins were blotted onto
nitrocellulose and filters were blocked in Tris-Buffered
Saline Tween-20 (TBST) containing 5% non-fat dried milk
for at least 1 h. To specifically detect transgenic human
cortactin, Western blots were incubated with the polyclo-
nal antibody RA444 [30] or monoclonal anti-cortactin
Esab157 (P13320-clone 30 from BD Biosciences
Pharmingen, USA). Both these antibodies did not cross-
react with mouse cortactin ([30] and data not shown).
Blots were stripped and reincubated with monoclonal
4F11 or polyclonal antibody RA23 to detect both trans-
gene (human) and endogenous (mouse) cortactin [30]. A
monoclonal antibody against actin (Mab1501R, Chemi-
con, Temecula, CA, USA) was used as loading control.
Blots were incubated with secondary anti-mouse or anti-
rabbit IgG-peroxidase conjugate (BD Biosciences
Pharmingen) and developed using the ECL enhanced
chemiluminescent detection system (Amersham).
Histology and immunohistochemical staining
From each sacrificed mouse, various tissues (lung, brain,
sketal muscle, heart, femur, spleen, kidney, mammary
glands [see first paragraph], salivary glands, colon, stom-
ach, uterus/ovary, liver, pancreas, lymph nodes) were
fixed in 4% formaldehyde in PBS, embedded in paraffin,
sectioned at 4 µm, routinely stained with haematoxylin
and eosin (HE) and microscopically examined by a
pathologist. For immunohistochemical staining of the
paraffin-embedded sections antigen retrieval was per-
formed by boiling the sections in a 0,01 M sodium citrate
buffer at pH = 6 for 10 min. Then, sections were blocked
for 30 min with 0,5% casein in PBS. The monoclonal anti-
body against cortactin (P13320) was conjugated with
FITC (SPC2476, BD Biosciences Pharmingen, USA) and
used as primary antibody in a dilution of 1:900 in PBS/
1% BSA and incubated overnight at 4°C. This antibody
was used because conventional mouse monoclonal anti-
bodies lead to background staining on mouse sections
when used in combination with a secondary rabbit anti-
mouse antibody. As secondary antibody, sheep anti-fluo-
rescein-POD (peroxidase conjugated) Fab fragments
BMC Cancer 2006, 6:58 http://www.biomedcentral.com/1471-2407/6/58
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(Roche) was used in a 1:300 dilution at room temperature
for 30 min, followed by treatment with DAB substrate
plus H2O2 (0.33%) (Merck, Darmstadt, Germany) for 10
min. Sections were lightly stained with haematoxylin and
embedded in mounting medium. The pancreas from each
mouse was as a positive control for staining.
Whole-mount staining
Abdominal mammary fat pads used for whole mount
staining were dissected from the pelt of transgenic and
control mice, spread on plastic gauze and fixed in 1:3 ace-
tic acid/ethanol solution for 60 min. The mammary fat
pads were than dehydrated in 70% ethanol (15 min),
Normal mammary gland development in cortactin transgene miceFigure 2
Normal mammary gland development in cortactin transgene mice. (A) Expression of endogenous and transgenic 
cortactin in mouse mammary epithelium at different stages of mammary gland development as determined by Western blot 
analysis. Total protein was loaded from the abdominal mammary gland of non-transgenic (W) and transgenic mouse line 16 (T) 
of virgin female mice (V), mice at day 11 and 17 of pregnancy (P11, P17), day 4, 10 and 17 of lactation (L4, L10, L17) and day 4 
and 8 of involution (I4, I8). Monoclonal antibody Esab157 was used to recognize specific human transgene expression, whereas 
monoclonal antibody 4F11 recognizes both human and mouse cortactin. Actin was used as a loading control. (B) Immunohis-
tochemical detection of cortactin transgene in a 10-days lactating mammary gland (L10). WT, wild type; T16, transgenic mouse 
line 16. About 50% of epithelial cells from the transgenic section stained positive for cortactin. Arrows indicate cortactin local-
ization at cell-cell contacts. Sections were counterstained with haematoxylin.
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rinsed in demineralised water, and stained overnight with
alum carmine (1 g carmine, 2.5 g alum potassium sul-
phate in 500 ml Millipore water). The stained pads were
washed in a series of ethanol steps (70%, 95%, and 100%,
respectively), and transferred to xylene for 1 hr. The
stained whole mounts were stored in methyl salicylate.
The presence of MIN or HAN was scored by eye and by
analysis of pictures of the whole mounts.
Statistical analysis
Survival curves of mice were analyzed with the statistical
software of SPSS 10, which uses log-rank tests to deter-
mine statistically significant differences between (tumor-
free) survival curves.
Results
Generation of MMTV-cortactin transgenic mice
To obtain transgenic mice that overexpress the human
cortactin protein in mammary epithelium, a construct was
generated using the 1.8-kb cDNA sequence encoding
human cortactin under transcription control of the ster-
oid-inducible mouse mammary tumor virus (MMTV)-
promoter (Fig. 1A). To test the steroid-inducibility of the
transgene, the MMTV-cortactin construct was transfected
in CAC-L153 mouse fibroblasts. Upon addition of the
glucocorticoid dexamethasone, the expression of the
human transgene was induced 10–40 fold compared to
unstimulated transfectants as reported previously [30]
(data not shown). Transgenic mice were generated by
microinjecting fertilized oocytes from FVB/N inbred mice
with this MMTV-cortactin construct. Three independent
MMTV-cortactin founders were selected with a low (T6),
an intermediate (T16) and a high (T14) DNA copy
number of the transgene (Fig. 1B). To determine trans-
gene expression, total mRNA and protein were isolated
from the abdominal mammary gland (MG) after 10-days
of lactation. In transgenic line T16, the human cortactin
transgene was highly expressed at both mRNA (Fig. 1C)
Normal mammary epithelium in cortactin and cyclin D1 nulliparous, but not in multiparous transgenic miceFigure 4
Normal mammary epithelium in cortactin and cyclin D1 nulliparous, but not in multiparous transgenic mice. 
(A) Whole mounts of the abdominal mammary gland from nulliparous mice of wild type (WT), cortactin transgenic (T16), cyc-
lin D1 transgenic (MP1) and cortactin/cyclin D1 bitransgenic (T16*MP1) mice at 20 weeks of age. The dark spot in the middle 
represents a lymph node. (B) Whole mounts of the abdominal mammary gland of post-weaned multiparous mice with mam-
mary intraepithelial neoplasia (MIN) and hyperplastic alveolar nodules (HAN, arrows). The age in weeks and the number of 
pregnancies that the mouse went through, are indicated between brackets.
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and protein level (Fig. 1D), whereas the transgene was
undetectable in lines T6 and T14. Also at other stages of
mammary gland development, no transgene expression
was detected in T6 and T14 (data not shown). The T16
human cortactin transgenic mice were selected for further
analysis.
We examined the expression pattern of the T16 transgene
in several tissues using Western blotting (Fig. 1E) and
immunohistochemistry (data not shown). In virgin trans-
genic mice, we detected transgene cortactin expression
only in the pancreas and not in other tissues including the
mammary gland (MG), salivary gland, lung, liver, spleen,
kidney and muscle (data not shown). When virgin mice
were treated with the glucocorticosteroid dexamethasone
to stimulate the MMTV promoter, transgene expression
was significantly induced in the MG (data not shown),
pancreas, liver, and kidney (Fig. 1E). T16 transgenic mice
developed normally, were fertile and had no overt pheno-
typic differences from wild-type mice. In male mice, trans-
gene expression was observed only in a few cells of the
prostate, but not in the MG or any other tissues/organs
(data not shown) and, therefore, no further analysis was
pursued with MMTV-cortactin transgenic male mice.
Thus, in the transgenic mouse line T16, expression of the
MMTV-driven human cortactin transgene is targeted to
the mammary gland.
Normal mammary gland development in MMTV-cortactin 
transgenic mice
To determine the temporal pattern of expression of the
cortactin transgene throughout MG development, the
abdominal MG of both T16 transgenic and non-trans-
genic FVB/N inbred mice were obtained from virgin (V)
mice, from mice at day 11 and 17 of pregnancy (P11,
P17), from day 4, 10 and 17 of lactation (L4, L10, L17)
and from day 4 and 8 of involution (I4, I8). All MGs were
analyzed by Northern blotting (data not shown), Western
blotting (Fig. 2A) and immunohistochemistry (Fig. 2B
and data not shown). The cortactin transgene was highly
expressed during lactation (L4, L10, L17), but not during
pregnancy and involution, whereas endogenous cortactin
was expressed during all stages in both WT and transgenic
mice (Fig. 2A). Immunohistochemistry (IHC) revealed
that the cortactin transgene was expressed in approxi-
mately 50% of the mammary epithelial cells and localized
in the cytoplasm, at the apical site of the cell (at the
lumen) and in cell-cell contacts (arrows), which is in
agreement with our in vitro data [35]. In all stages of MG
development, no macroscopic (whole-mounts) or micro-
scopic (HE and IHC stainings) morphological changes
were observed in the MMTV-cortactin mice compared to
the WT mice (Fig. 2B for L10, Fig. 4A for virgin, other
stages data not shown). In agreement with these observa-
tions, T16 transgenic mice are able to normally breastfeed
their pups. Taken together, MMTV-cortactin mice express
human cortactin at high levels in the lactating MG with-
out any detectable morphological consequences.
MMTV-cortactin transgenic mice neither develop (pre-
malignant) breast tumors nor accelerate MMTV-cyclin D1-
induced mammary tumorigenesis
The role of cortactin overexpression on MG tumor devel-
opment in vivo, either in the absence or presence of co-
expression of cyclin D1, was studied in a cohort of 100
multiparous mice that underwent multiple pregnancies/
lactations to force transgene expression in the MG. By
intercrossing MMTV-cortactin mice (T16) with MMTV-
cyclin D1 mice (MP1 [14]), the cohort was composed of
28 MMTV-cortactin mice (T16), 15 MMTV-cyclin D1 mice
(MP1), 23 MMTV-cortactin/MMTV-cyclin D1 mice
(T16*MP1) and 34 wild-type mice (WT, MMTV-cortactin
and MMTV-cyclin D1 negative mice). MG tumors were
observed in 6 out of 28 MMTV-cortactin T16 transgenic
mice (21%). By histological examination 6 tumors were
classified as adeno(squamous) carcinomas (Table 1 and
2). One mouse had a tumor partly consisting of adeno
and partly of spindle cell carcinoma. One mouse had two
tumors, an adenosquamous and a cribriform carcinoma.
For breast tumorigenesis studies, we have used FVB/N
strain to generate transgenic mice because of its reported
low incidence of MG tumors [36]. Unexpectedly, in our
cohort of 34 WT FVB/N mice, we observed 13 mice with
MG carcinomas (38%, 11 adeno(squamous), 3 spindle
cell, 1 cribriform and 1 endocrine carcinoid, Table 1 and
2). MG tumors were observed in 6 out of 15 (40%)
MMTV-cyclin D1 mice: 4 adenosquamous, 1 papillary, 1
cribriform and 1 endocrine carcinoid carcinoma. One
mouse had even 3 tumors. And finally, in the cohort of 23
bitransgenic T16*MP1 mice, 7 mice bore MG tumors
(30%), 6 adeno(squamous) and 1 papillary carcinoma
(Table 1 and 2). These data revealed that the incidence of
MG tumors in the non-transgenic FVB/N mice (38%) is
similar to MMTV-cyclin D1 (40%) mice and almost twice
as high than in MMTV-cortactin (21%) or MMTV-cyclin
D1/cortactin bitransgenic mice (30%). When comparing
the histology of the MG tumors between the transgenic
and WT mice, it is remarkable that most MG tumors from
WT, T16 or T16*MP1 mice are of adeno(squamous) ori-
gin (11/16, 6/7 and 6/7, respectively). Thus, the origin of
MG tumors in MMTV-cortactin mice is comparable to WT
mice. In MMTV-cyclin D1 (MP1) mice only half of the
tumors are from adeno(squamous) origin (4/8), which is
in agreement with previous results [14]. This suggests that
the origin of the non-adenosquamous carcinomas in
MMTV-cyclin D1 mice might be caused by cyclin D1
expression and might be repressed in the T16*MP1
bitransgenic mice. In summary, our data suggest that the
MMTV-cortactin transgenic mice neither develop breast
tumors nor accelerate MMTV-cyclin D1-induced mam-
BMC Cancer 2006, 6:58 http://www.biomedcentral.com/1471-2407/6/58
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mary tumorigenesis on top of the causal MG tumors that
arose in the aged FVB/N mice.
In figure 3A, the incidence of mammary tumors is
depicted as the appearance of mammary tumor as func-
tion of time (% mammary tumor free mice). None of the
three transgenic lines showed a statistically significant ear-
lier onset of MG tumor development compared to WT
FVB/N (log rank test). MG tumors of all four genotypes
arose stochastically with a long latency period (mean age
of MG tumor onset was between 89 and 100 weeks, Table
1). From figure 3A, we can conclude that most mice in our
cohort were not sacrificed because of the appearance of
MG tumors (indicated as +, censored). Therefore, we per-
formed Kaplan Meier overall survival curves (Fig. 3B) that
revealed that only MMTV-cyclin D1 (MP1) and bitrans-
genic (T16*MP1) (but not MMTV-cortactin transgenic)
mice died significantly earlier than WT mice (p = 0,034
and p = 0,017, respectively, log rank test). Taken together,
we conclude that the development of malignant breast
tumors in either WT or MMTV-cyclin D1 mice was not
increased due to overexpression of human cortactin.
Two month old nulliparous MMTV-cyclin D1 MP1
females have been shown to develop hyperplasia [14]. We
examined the occurrence of pre-malignant lesions as
determined by mammary intraepithelial neoplasia (MIN)
and hyperplastic alveolar nodules (HAN) in whole
mounts and HE stainings of mammary glands of 20 (Fig.
4A), 29 and 35 weeks (data not shown) old nulliparous
WT, T16, MP1 and T16*MP1 mice. We did not observe
hyperplastic lesion in any of the nulliparous mice of these
ages. In contrast, we observed many MIN with or without
HAN in older multiparous mice (Fig. 4B whole mounts
and Fig. 5A,B). In fact, we observed pre-cancerous MIN
and HAN lesions in all four transgenic lines (Table 1) and
no significant differences were found compared to WT
FVB/N mice. Immunohistochemical stainings revealed
that only 1 out of 21 examined MGs of the T16 line
showed transgenic cortactin expression in HAN and none
of the 14 examined MGs from line T16*MP1. In addition,
we did not detect any cortactin transgene expression in
MG tumors of either T16 or T16*MP1 bitransgenic mice
(5 MG tumors examined of each line, data not shown).
Taken together, none of the MG abnormalities observed
in MMTV-cortactin mice were different from WT FVB/N
mice. In agreement with this, none of the carcinomas and
pre-cancerous lesions showed transgene expression
despite high transgene expression during lactation in this
transgenic mouse strain.
More recently, from cell biological and biochemical anal-
yses it is clear that cortactin is involved in remodeling the
actin cytoskeleton via Arp2/3 mediated actin polymeriza-
tion, especially its new role in mediating intercellular
adhesions and cell spreading [35,37,38]. Deregulation of
these processes by overexpression of cortactin might
mediate the migratory and invasive potential of tumor
cells. This implies that mammary gland tumors in the
MMTV-cortactin transgenic mice might show an increased
incidence of distant metastasis. For that purpose we
screened microscopically numerous organs (especially the
lung and liver) for the presence of metastatic breast tumor
cells at time the mice were sacrificed. We observed lung
tumors in 2 of 6 (line T16) and 3 of 7 (line T16*MP1)
mice with MG tumors (Table 2). However, histological
examination excluded them as being metastasis but iden-
tified them as primary tumors. Moreover, in our cohort of
multiparous mice, we observed a lung-tumor incidence
between 30% and 50% in all four transgenic lines (data
not shown), indicating a relatively high background of
spontaneous lung tumors without any direct link to MG
tumors.
Discussion
We investigated the involvement of cortactin in mammary
gland tumorigenesis in MMTV-cortactin and MMTV-cort-
actin/-cyclin D1 bitransgenic mice. Cooperative action of
Table 1: The incidence of mammary gland tumors in multiparous mice. The pathology of mammary tumors and premalignant lesions 
were assessed according to the consensus report from the Annapolis meeting on the mammary pathology of genetically engineered 
mice [33]. WT, wild type; T16, MMTV-cortactin mice; MP1, MMTV-cyclin D1 mice; T16*MP1, bitransgenic mice; wk, weeks; % MG T = 
no. of mice with mammary gland tumors per total no. mice; a.s.car = adeno(squamous)carcinoma of the MG; other MG car. = other 
MG carcinoma (see table 2); Some mice beared more than one MG carcinoma (see table 2). MIN = mammary intraepithelial 
neoplasia; HAN = hyperplastic alveolar nodules. MIN+HAN = no. of mice bearing MIN and/or HAN.
No. of mice % MG T a.s.car. MG other MG car. mean age of MG tumor 
onset (wk)
MIN HAN HAN+MIN
WT FVB/N 34 13 (38%) 11 (32%) 5 (15%) 97 21 (62%) 22 (65%) 26 (76%)
T16 (cortactin) 28 6 (21%) 6 (21%) 1 (4%) 100 15 (55%) 19 (68%) 23 (82%)
MP1 (cyclin D1) 15 6 (40%) 4 (27%) 4 (27%) 91 7 (47%) 9 (60%) 13 (87%)
T16 * MP1 23 7 (30%) 6 (26%) 1 (4%) 89 8 (35%) 14 (61%) 15 (65%)
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Table 2: Description of animals bearing mammary gland tumors. The pathology of mammary tumors and premalignant lesions were 
assessed according to the consensus report from the Annapolis meeting on the mammary pathology of genetically engineered mice 
[33]. WT, wild type; T16, MMTV-cortactin mice; MP1, MMTV-cyclin D1 mice; T16*MP1, bitransgenic mice; wk, weeks; pregn, 
pregnancies; MG, mammary gland; d, diameter; cm, centimeter; HAN, hyperplastic alveolar nodules; MIN, mammary intraepithelial 
neoplasia; hyp, hypofyse enlargement (+); carc, carcinoma; IHC-, cortactin immunohistochemical staining negative; Y, yes; N, no; nd, 
not done.
Animal Age (wk) No. of pregn MG tumor Size (d,cm) No. of HAN MIN Lung 
tumor
Hyp Metas tasis
WT
N.1 103 4 spindle cell 0.8 7 Y N -
N.2 93 5 adenosquamous carc. + 
transformation to spindle cell
1.0 3 Y N -
N.3 108 6 2 adenosquamous carc. + 1 
cribriform
1.0
0.4
8 Y Y, carc. +
N.4 111 4 adenosquamous carc. 0.3 3 N Y -
N.5 102 6 adeno carc. 0.8 6 Y N -
N.6 127 5 adenosquamous carc. 0.5 8 Y N -
N.7 78 7 adeno carc. 0.7 1 Y Y,carc. -
N.8 118 5 adenosquamous carc. 0.5 10 Y Y - liver
N.9 91 5 adenosquamous carc. 0.2 2 Y Y,carc. -
N.10 63 5 adeno carc. 1.0 6 Y N -
N.11 102 5 spindle cell 0.8 5 Y N +
N.12 61 5 neuroendocrine carcinoid 1.0 0 Y Y nd lung
N.13 105 4 adenosquamous carc. 0.4 0 N N nd
T16
N.1 90 6 adenosquamous carc. (IHC-) 1.0 4 Y N nd
N.2 120 4 adenosquamous carc. (IHC-) 0.5 5 Y N -
N.3 60 2 part adeno carc. + part spindle 
cell (IHC-)
2.0 3 Y Y - lung (?)
N.4 113 5 adenosquamous carc. (IHC-) 0.8 3 N N -
N.5 109 5 adenosquamous carc. 0.3 4 N Y -
N.6 108 5 cribriform + adenosquamous 
carc.(IHC-)
1.0 7 Y N +
MP1
N.1 97 5 2 adenosquamous carc. 0.5 7 Y N -
1 papillair carc. 0.5
N.2 100 6 papillair carc. 0.4 0 Y Y -
N.3 53 7 endocrine carcinoid 2.0 0 N N -
N.4 100 4 adenosquamous carc. 0.3 3 N N -
N.5 98 3 adenosquamous carc. 2.0 0 Y Y - lung
N.6 101 5 cribriform 2.0 2 N Y -
T16*MP
N.1 69 2 adeno carc. (IHC-) 1.5 2 N N -
N.2 117 7 adenosquamous carc. (IHC-) 0.2 3 Y Y -
N.3 95 3 adenosquamous carc. (IHC-) 0.2 4 Y N -
N.4 101 4 papillair carc. 0.8 0 Y Y,carc -
N.5 93 5 adenosquamous carc. (IHC-) 0.2 3 Y Y,carc -
N.6 95 4 (adeno)squamous carc. (IHC-) 1.0 4 N N -
N.7 55 5 (adeno)squamous carc. 1.0 0 Y N -
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cortactin in an MMTV-cyclin D1 background might affect
the onset, the type or the aggressiveness of MG tumors
(invasion or formation of metastasis). In this study, we
found that cortactin did not provide any advantage in
mammary gland tumor development. However, several
circumstances might have influenced our results.
Firstly, the site of integration of a transgene can influence
the timing of the transgene expression and may be respon-
sible for the lack of an effect of cortactin on tumorigenesis.
Indeed, the cortactin transgenic lines T6 and T14 with
respectively a low and high copy number of the transgene,
did not express the cortactin transgene during any stage of
gestation. This indicates that the integration site and/or
the copy number somehow determine the accessibility of
the MMTV promoter. On the other hand, in the cortactin
transgenic line T16, we observed transgene expression but
that was restricted to the stage of lactation and not detect-
able during pregnancy, involution or in the virgin MG. For
tumor development generally cell division is necessary.
The fact that the cortactin transgene was not
(over)expressed during pregnancy, the phase of cell divi-
sion in the mammary gland, implies that the window of
increased cortactin might have been too narrow to affect
mammary gland tumorigenesis. This is most probably not
due to the use of MMTV promoter itself, because in several
other transgenic mice models to study mammary tumori-
genesis such as MMTV-kgf [39] and MMTV-Cdc25B [40],
the MMTV-driven transgene was expressed during all
stages of gestation. Thus, transgene integration may have
influenced expression pattern of the transgene in line T16
and may explain the lack of effect of cortactin on tumori-
genesis.
Secondly, the MMTV-cortactin and MMTV-cyclin D1 mice
were generated in a FVB/N inbred background. The FVB/
N strain was created in the early 1970s and has since been
extensively used in transgenic research because of its well-
defined inbred background, superior reproductive per-
formance, and prominent pronuclei of fertilized zygotes,
which facilitates microinjection of the transgene [41]. Lit-
tle is known, however, about the survival and spontane-
ous diseases of non-transgenic FVB/N multiparous mice.
In agreement with our cohort of multiparous FVB/N mice,
recently Nieto et al. [42] also observed spontaneous mam-
mary hyperplasia and mammary tumors in 4 out of 6
multiparous mice younger than 70 weeks. In some cases
mammary hyperplasia was due to pituitary abnormalities
[43], because prolactin secreted by the pituitary gland, is
an important stimulator of mammary gland development
[44]. We observed three enlarged pituitaries in multipa-
rous mice bearing mammary gland tumors (Table 2) indi-
cating that these mammary gland tumors might be the
consequence of a pituitary disorder. However, we did not
examine prolactin concentrations to study this possibility.
In transgenic mice with a strong penetrance of the trans-
gene such as c-neu, Ha-ras or c-myc [15-17], the onset of
mammary gland tumors was so early (mean age of 3, 6,
and 11 months, respectively) that spontaneous diseases
due to the background of the strain did not interfere with
the results. However, in transgenic mice with a very low
penetrance, tumors arise stochastically with a very long
latency period. Furthermore, palpable mammary gland
tumors, even when very large (> 1,5 cm), are never lethal
by itself. This means that mice get old and finally die
because of age related diseases [36]. As a result, specific
phenotypes of transgenes with a low penetrance are not
able to manifest themselves or were not observed due to
the background disorders of aged-matched mice. In our
study, overexpression of human cortactin did not acceler-
ate the development of (pre-malignant) breast tumors
(Fig. 3A) and had no significant effect on overall survival
(Fig. 3B) in either WT or MMTV-cyclin D1 mice, suggest-
ing that cortactin also might act as a low penetrance trans-
gene.
In our cohort of 15 MMTV-cyclin D1 mice, we observed 6
mice with mammary gland tumors (40% incidence) at a
mean age of 91 weeks. In the original study, 5 out of 9
MMTV-cyclin D1 (MP1) mice developed mammary
tumors with a mean age of 76 weeks [8]. In another study
with MMTV-cyclin D1 (MP1) transgenic mice, 8 out of 16
mice developed mammary tumors with a mean age of 113
weeks (in an FVB/N versus FVB/SV129 background) [45].
The reason for this discrepancy in the timing of mammary
tumor development is unclear and is in our opinion not
only due to the mixed (FVB/N/SV129) genetic back-
ground as was suggested because we also observed a long
latency in a full FVB/N background. In addition, in the lat-
ter study, mammary gland tumor incidence of MMTV-cyc-
lin D1 did not achieve statistical significance compared to
wild type mice that developed MG tumors in 3 out of 10
mice as well, which is in agreement with our study (this
manuscript) and the findings of Wakefield et al. [43]. Fur-
thermore, we did not observe hyperplasia in nulliparous
MMTV-cyclin D1 female mice as has previously been
shown [14] nor in nulliparous MMTV-cortactin/-cyclin
D1 bitransgenic mice. We did observe premalignant
lesions in all multiparous transgenic mice, but also in
multiparous FVB/N control mice. In addition, premalig-
nant lesions did not express the cortactin transgene. Taken
together, our cohort of multiparous MMTV-cyclin D1
mice was less potent in promoting mammary hyperpla-
sias and carcinomas as has previously been shown and
MMTV-cortactin did not accelerate the incidence of hyper-
plasia or MG tumors in bitransgenic mice. This is due to
the long latency period and the background disorders of
the FVB/N strain, which emphasizes the importance of
control animals.
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Thirdly, in human cancer overexpression of cortactin is
correlated with metastasis formation. Cells overexpressing
cortactin show enhanced migration and invasion in vitro
[22-24]. In addition, overexpression of cortactin in MDA-
MB-231 breast cancer cells did not affect the growth rate,
but promoted the formation of bone metastases [25]. In
this study, we did not observe metastases in the MMTV-
cortactin (bi)transgenic mice bearing MG tumors, which
might be due to the long latency of MG tumor onset and
the short lifetime of the mice. It is also possible that
micrometastases have developed in the MMTV-cortactin
(bi)transgenic mice, but were not detected by the analysis
we performed. An effect of cortactin overexpression on
metastasis formation in vivo, can possibly be achieved by
crossing the MMTV-cortactin mice with high penetrance
transgenic mice (e.g. MMTV-myc, -ras or -neu) to acceler-
ate the onset of mammary gland formation. This will give
the primary tumor the opportunity to develop metastasis
during a mouse lifespan.
Our results demonstrate that mammary gland targeted
cortactin did not affect mammary epithelial cell morphol-
ogy and did not provide proliferative advantages in the
development of (pre-malignant) breast tumor in either
WT or MMTV-cyclin D1 transgenic mice. In conclusion, at
least in our transgenic model cortactin seems not to have
a causative role in breast cancer, but appears to be a weak
mammary oncogene. This study further supports the
notion that cancer development and progression is a
multi-step process and mutation of two or more genes
may be required for cell transformation in mammary epi-
thelial cells.
Our analysis demonstrated a high incidence of benign
and malignant abnormalities in the mammary glands in
the parental "control" FVB mice (see above). Many trans-
genic mouse models for breast cancer are generated in a
background of FVB [41], however, our study (this manu-
script) and two recent studies [42,43,45] illustrate that
this FVB-background might not be suitable for all breast
cancer studies. In addition, we observed many more
abnormalities in other organs (not shown), the most
common being primary lung carcinomas at an incidence
of ~40% in parous as well as non-parous old FVB mice
(data not shown) which is consistent with previously
reported data [36]. The high incidence of these abnormal-
ities in the mammary gland, lung and other organs has
important consequences for the interpretation of new
phenotypes in transgenic mice in a FVB-background.
Conclusion
To mimic the 11q13 amplification, as seen in several
human cancers, and to investigate the involvement of
cortactin in mammary gland tumorigenesis and a possible
cooperative action of cortactin and cyclin D1, we gener-
ated MMTV-cortactin transgenic and MMTV-cyclin D1/-
cortactin bitransgenic mice. From this study, we can con-
clude that development of (pre-malignant) breast tumors
in either wild type or MMTV-cyclin D1 mice was not aug-
mented due to mammary gland targeted overexpression
of human cortactin. In addition, our analysis demon-
strated a high incidence of benign and malignant abnor-
malities in the mammary glands in the parental "control"
FVB mice, which have important consequences for the
interpretation of new phenotypes in transgenic mice in a
FVB-background.
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Abnormal mammary gland morphologyFigure 5
Abnormal mammary gland morphology. Photographs of HE stained sections of representative abdominal mammary 
glands of post-weaned multiparous mice with (A) normal mammary gland epithelium; (B) mammary intraepithelial neoplasia 
(MIN); (C) hyperplastic alveolar nodules (HAN) or adenosquamous adenoma; (D) adenosquamous carcinoma; (E) papillary 
carcinoma; (F) cribriform carcinoma; (G) adeno carcinoma; and (H) spindle cell carcinoma. All pictures are taken with the 
same magnification except (H), which is taken with a two times higher magnification.
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